My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

59 60 Next >

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

3 Cheap Growth Stocks to Buy in 2025 ↗

January 09, 2025

Via The Motley Fool

Better Buy: Novo Nordisk vs. AstraZeneca ↗

January 04, 2025

Via The Motley Fool

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million ↗

January 02, 2025

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including clinical trials by 2025.

Via Benzinga

Is AstraZeneca Stock a Buy? ↗

December 22, 2024

Via The Motley Fool

Why IonQ Is the Best Quantum Computing Stock to Buy Right Now ↗

December 26, 2024

Via The Motley Fool

Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts ↗

December 24, 2024

Achilles Therapeutics announces a $12M deal with AstraZeneca for TRACERx data and plans job cuts following its strategic review.

Via Benzinga

Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗

December 18, 2024

Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.

Via Investor's Business Daily

FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer ↗

December 17, 2024

The FDA delays Johnson & Johnson's SC amivantamab approval for NSCLC over facility inspection issues, unrelated to product safety or efficacy

Via Benzinga

3 Unstoppable Stocks to Buy Right Now ↗

December 15, 2024

Via The Motley Fool

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗

December 13, 2024

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.

Via Benzinga

United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis ↗

December 13, 2024

An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains.

Via Benzinga

AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients ↗

December 11, 2024

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results in ovarian cancer.

Via Benzinga

2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer ↗

December 09, 2024

Via The Motley Fool

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder ↗

December 06, 2024

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks.

Via Benzinga

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer ↗

December 06, 2024

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients.

Via Benzinga

FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer ↗

December 05, 2024

AstraZeneca's Imfinzi gains FDA approval for LS-SCLC after ADRIATIC trial shows survival benefits. Separate trials explore additional cancer therapies.

Via Benzinga

Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons' ↗

December 03, 2024

Via Benzinga

3 Momentum Stocks Soaring Into 2025 and Beyond

December 03, 2024

Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.

Via MarketBeat

Topics Stocks

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

November 28, 2024

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

Via MarketBeat

Topics Government

AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns ↗

November 21, 2024

FDA panel to discuss AstraZeneca's supplemental application for Andexxa amid safety concerns, including thrombosis risks and efficacy limitations.

Via Benzinga

3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now ↗

November 21, 2024

Via The Motley Fool

This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday ↗

November 20, 2024

Via Benzinga

Not-So-Big Pharma ↗

November 16, 2024

Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.

Via Talk Markets

European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗

November 15, 2024

Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.

Via Benzinga

Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It ↗

November 15, 2024

Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38.

Via Benzinga

WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill ↗

November 15, 2024

Trump's decision to appoint Kennedy, known for his vaccine skepticism, has sparked significant attention.

Via Benzinga

Topics Government

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower ↗

November 14, 2024

Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks.

Via Benzinga

Topics Government

Is AstraZeneca a Buy as It Eyes the Weight Loss Market? ↗

November 14, 2024

AstraZeneca just released some encouraging data about its weight loss drug candidates.

Via The Motley Fool

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease ↗

November 13, 2024

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.